Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Shimadzu Corporation    7701   JP3357200009

SHIMADZU CORPORATION

(7701)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Shimadzu : Tohoku University and Shimadzu Jointly Announce a New Breath Test for Detecting COVID-19

11/12/2020 | 09:19am EST

Tohoku University announced the development of a non-invasive breath testing technology for COVID-19 through collaboration with Shimadzu Corporation, the leading provider of analytical instruments and solutions. The technology termed 'breathomics' analyzes viral and host biomolecules contained in breath aerosols that can be collected by freely breathing into the newly-developed device for five minutes. The research team aims to further apply the breathomics technology to other infectious and non-infectious diseases to bring closer the future health monitoring based on breath sampling.

Research Abstract

For minimizing both spread of COVID-19 and health hazard caused, there is an urgent need for an effective test that can simultaneously screen the disease and give other diagnostic indications such as disease severity and prognosis. To this end, Tohoku University Graduate School of Medicine and the Institute of Aging Medicine, in collaboration with Shimadzu Corporation, worked on the development of the breathomics analysis system to combat SARS-Cov-2 pandemic and more.

The system developed here utilizes a technology termed 'breathomics', which means comprehensive analysis of biological components in exhaled aerosol using mass spectrometry. Its major benefits over other testing techniques are non-invasive nature of aerosol sampling and the wealth of information that can be associated with various biological implications.

For aerosol sample collection, Tohoku University developed the high-performance collection device that acquires approximately 1 mL of exhaled breath condensate (EBC) by the subject's own manipulation in five minutes of breathing at rest. Hence the system allows for future point-of-care testing needed for early detection and safe isolation of infected personnel.

The multifaceted analysis data delivered by the system include the levels SARS-Cov-2 proteins, other viral proteins, and the host proteins and metabolites involved in inflammatory responses. In addition to giving direct indication of viral infection, results can be used to evaluate the stage and conditions of the disease, to estimate the risk of disease progression, and to predict prognosis and complications. Further studies with additional input may enable prediction of metabolic diseases such as cardiovascular and pulmonary diseases, lifestyle-related diseases, arteriosclerosis, diabetes, cancer, and health management for preventive medicine. As such, we aim to bring closer the future form of personalized and remote healthcare system which we call 'breath medicine'.

*For Research Use Only. Not for use in diagnostic procedures

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about SHIMADZU CORPORATION
01/07SHIMADZU : Celebrating 60th Anniversary of Remote Fluoroscopy System for Radiati..
AQ
2020SHIMADZU CORPORATION : - Decreasing the Workload of Medical Professionals and In..
AQ
2020SHIMADZU : introduces lower-priced automated coronavirus test machine
AQ
2020SHIMADZU : Tohoku University and Shimadzu Jointly Announce a New Breath Test for..
AQ
2020SHIMADZU : New Imaging System Enables Integrated Analysis of Both Trace Elements..
AQ
2020SHIMADZU CORPORATION : half-yearly earnings release
2020Global Glycobiology Market to Rise at 14.64% between 2020 and 2027
AQ
2020SHIMADZU CORPORATION : Ex-dividend day for interim dividend
FA
2020SHIMADZU : Acquisition of the approval for marketing the Novel Coronavirus (SARS..
AQ
2020SHIMADZU'S RESPONSE TO THE COVID-19 : Helping People Respond to the Pandemic
AQ
More news
Financials
Sales 2021 370 B 3 564 M 3 564 M
Net income 2021 29 322 M 283 M 283 M
Net cash 2021 86 872 M 837 M 837 M
P/E ratio 2021 41,3x
Yield 2021 0,72%
Capitalization 1 210 B 11 666 M 11 659 M
EV / Sales 2021 3,04x
EV / Sales 2022 2,84x
Nbr of Employees 13 182
Free-Float 96,9%
Chart SHIMADZU CORPORATION
Duration : Period :
Shimadzu Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHIMADZU CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 4 305,00 JPY
Last Close Price 4 105,00 JPY
Spread / Highest target 16,9%
Spread / Average Target 4,87%
Spread / Lowest Target -19,6%
EPS Revisions
Managers and Directors
NameTitle
Teruhisa Ueda President, CEO & Representative Director
Akira Nakamoto Chairman
Shin Bandai Manager-Finance & Accounting
Yasunori Yamamoto Head-Information Systems & Manufacturing
Hiroshi Fujino Director & Senior Managing Executive Officer
Sector and Competitors
1st jan.Capitalization (M$)
SHIMADZU CORPORATION2.37%11 525
SMC CORPORATION6.89%43 550
METTLER-TOLEDO INTERNATIONAL, INC.6.91%28 992
COGNEX CORPORATION4.68%14 676
MKS INSTRUMENTS, INC.18.05%9 792
RENISHAW PLC0.00%5 698